The appeal is the latest move in the compounders’ battle to continue making copies of tirzepatide and other GLP-1s, including semaglutide. The FDA declared an end to the 2-year-old tirzepatide ...

In one of the first real-world studies, Tirzepatide shows impressive weight loss results for people without diabetes—shedding nearly 13% of body weight in just six months. Study: Real-world use ...

1 This denial keeps in place the FDA’s declaratory order determining that the shortage of diabetes and weight-loss tirzepatide products has been resolved and phases out compounded tirzepatide ...

A recent study published in Diabetes Technology & Therapeutics has demonstrated that off-label use of semaglutide and tirzepatide leads to significant reductions in glycated haemoglobin (HbA1c ...

Adults with type 1 diabetes had greater declines in HbA1c and body weight 1 year after being prescribed semaglutide or tirzepatide. Randomized controlled trials are needed to assess efficacy and ...

A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture knockoff versions of Eli Lilly's tirzepatide while a lawsuit plays out.

Investing.com -- Hims & Hers Health shares are down over 8% premarket Thursday after a federal judge ruled in favor of the FDA in the tirzepatide compounding case. Bank of America wrote in a ...

By removing both semaglutide and tirzepatide (the actives in Wegovy and Zepbound, respectively) from its drug shortage list, the agency is cutting off the primary legal route that allows ...

(Image Credits: Pexel) A new study has revealed that off-label use of semaglutide (Ozempic) and tirzepatide (Mounjaro) leads to significant reductions in HbA1c levels and body weight among adults ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

Hollie Adams/Reuters In October, a compounding industry group, the Outsourcing Facility Association, filed a lawsuit against the FDA's decision that there was no longer a shortage of tirzepatide ...